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Abstract
Background: Neuropathic pain, caused by a lesion or a disease affecting
the somatosensory system, is one of the most common complications in
diabetic patients. The purpose of this study is to identify genetic factors
contributing to this type of pain in a general diabetic population.
Method: We accessed the Genetics of Diabetes Audit and Research
Tayside (GoDARTS) datasets that contain prescription information and
monofilament test results for 9439 diabetic patients, among which 6927
diabetic individuals were genotyped by Affymetrix SNP6.0 or Illumina
OmniExpress chips. Cases of neuropathic pain were defined as diabetic
patients with a prescription history of at least one of five drugs specifically
indicated for the treatment of neuropathic pain and in whom
monofilament test result was positive for sensory neuropathy in at least
one foot. Controls were individuals who did not have a record of receiving
any opioid analgesics. Imputation of non-genotyped SNPs was performed
by IMPUTE2, with reference files from 1000 Genomes Phase I datasets.
Results: After data cleaning and relevant exclusions, imputed genotypes
of 572 diabetic neuropathic pain cases and 2491 diabetic controls were
used in the Fisher’s exact test. We identified a cluster in the Chr8p21.3,
next to GFRA2 with a lowest p-value of 1.77 × 10−7 at rs17428041. The
narrow-sense heritability of this phenotype was 11.00%.
Conclusion: This genome-wide association study on diabetic neuropathic
pain suggests new evidence for the involvement of variants near GFRA2
with the disorder, which needs to be verified in an independent cohort and
at the molecular level.
1. Introduction
Neuropathic pain is defined as pain directly caused by
a lesion or a disease affecting the somatosensory
system (Jensen et al., 2011). Although many common
diseases are associated with neuropathic pain (such as
herpes zoster), diabetes is one of the most common
causes (Belfer and Dai, 2010). Satisfactory relief of
neuropathic pain is achieved in less than 30% of these
patients, with consequent significant detriment to the
quality of life of the remaining individuals (Barrett
et al., 2007). In addition, the disorder represents a
significant economic burden to health-care systems
(Tarride et al., 2006; Dworkin et al., 2010).
Epidemiological studies have proposed multiple risk
factors associated with neuropathic pain from cross-
sectional studies, including older age, female gender,
manual occupation, lower educational attainment,
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living in a rural area or poor accommodation
(Torrance et al., 2006; Smith et al., 2007). Additional
risk factors for diabetic neuropathic pain have been
proposed, including smoking, hypertension, obesity,
hypercholesterolaemia and duration of diabetes
(Tesfaye et al., 2005; Jensen et al., 2006). Epidemio-
logical studies can identify risk factors and effective
preventive strategies in parallel with the search for the
underlying causative biological mechanisms, such as
genetic pathways (Smith et al., 2007).
Understanding the genetic factors associated with
neuropathic pain would assist in identifying the
underlying causal mechanisms and potentially indi-
cate molecular targets for pharmacological research.
Animal models have been widely applied in genetic
research in neuropathic pain. The heritability of neu-
ropathic pain was estimated to be around 30% in rat
models (Devor et al., 2005). Global gene expression
changes were observed in dorsal root ganglions and
the spinal cord in the spinal nerve ligation model of
neuropathic pain using rats (Wang et al., 2002). These
genes include immediate early genes; genes encoding
ion channels and signalling molecules that contribute
to the excitability of neurons; and genes that are
indicative of secondary events such as neuroinflam-
mation. Chessell et al. (2005) reported that P2X7 puri-
noceptor gene is essential for neuropathic pain. Trang
et al. (2009) proposed that P2X4 receptors in the rats’
microglia cells activated by peripheral nerve injury
lead to neuropathic pain via the release of brain-
derived neurotrophic factor. Other studies in mouse
models reported that TLR4 and CACNG2 genes are
involved in neuropathic pain (Nissenbaum et al.,
2010; Wang et al., 2013). Several candidate genes for
neuropathic pain therefore exist, although none has
been firmly confirmed or replicated in further human
studies. Recent family studies and twin studies have
found important genetic factors involved in pain per-
ception in humans (Norbury et al., 2007). Genome-
wide association study (GWAS) is a useful and efficient
method to identify potential candidate genes for
common complex disorders using DNA chips
(McCarthy et al., 2008). The DNA chips can genotype
hundreds of thousands of single nucleotide polymor-
phisms (SNP) in individuals, comparing variants
between cases and controls. So far, no GWAS has been
performed specifically on neuropathic pain.
To identify the genetic factors associated with neu-
ropathic pain in diabetes, we performed this GWAS
using a UK-based diabetic population.
2. Methods
2.1 Participants
We used the datasets from the Genetics of Diabetes Audit
and Research Tayside (GoDARTS) project in this study. The
project recruits consented patients with type 2 diabetes and
non-diabetic matching controls throughout Tayside, Scot-
land, to identify genetic factors related to diabetes, including
susceptibility, complications and response to treatment. Par-
ticipants attend for a simple baseline clinical examination
and complete a lifestyle questionnaire as well as provide
blood and urine samples. The consent provided by partici-
pants at the time of recruitment not only allows the use of
their data and samples (including extracted DNA) for
research purposes but also allows the data to be linked
anonymously to datasets derived from patients’ medical
records. These datasets include prescribing data, hospital
admissions, outpatient appointments and Scottish Care
Information-Diabetes Collaboration (SCI-DC) – an electronic
health record used by health-care professionals throughout
Scotland for the care of patients with diabetes. Further infor-
mation, including data access procedures, is available at
http://diabetesgenetics.dundee.ac.uk/. The GoDARTS study
has been approved by Tayside Committee on Medical
Research Ethics and informed consent was obtained from all
patients (REC reference 053/04).
So far, the project had recruited 9439 patients and 6927 of
them had been genotyped. For this study, we examined
GoDARTS data derived from linked records on routine
health care on participants’ prescription history from the
date of recruitment to June 2011, and monofilament testing
results for the presence of peripheral sensory neuropathy, as
well as directly provided data on age, gender and body mass
index (BMI). The monofilament test is a simple neurological
test carried out annually on diabetic patients to check
peripheral sensation. A monofilament is pressed at various
sites on both feet with approximately 10 g of pressure for a
short time (2 s) (Booth, 2000). Absence of sensation in at
least two out of five sites in one foot is a positive test,
considered indicative of likely peripheral neuropathy
(Booth, 2000).
What’s already known about this topic?
• There is currently no published hypothesis-free
genome-wide association study on neuropathic
pain. The genetic contribution of neuropathic
pain is poorly understood.
What does this study add?
• This genome-wide association study on diabetic
neuropathic pain suggests an association of chro-
mosome 8p21.3 with diabetic neuropathic pain.
It also provides a calculated narrow-sense heri-
tability of this trait and confirms that neuro-
pathic pain is a modestly heritable trait.
GWAS on neuropathic pain W. Meng et al.
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2.2 Deﬁnition of neuropathic pain cases
and controls
A neuropathic pain case was defined in this study as a type
2 diabetic individual with a history of at least one prescrip-
tion of any of the following five medicines, which are effec-
tive and recommended in diabetic peripheral neuropathy
(Attal et al., 2010; Finnerup et al., 2010; NICE, 2013) and
used less frequently for other indications: duloxetine, gaba-
pentin, pregabalin, capsaicin cream/patch and lidocaine
patch. The cases also had positive monofilament tests in
at least one foot, indicating the likely presence of sensory
neuropathy.
A control was defined as a type 2 diabetic individual with
no prescription history of these five drugs, nor of the follow-
ing 16 opioid analgesics (buprenorphine, codeine phosphate,
diamorphine, dihydrocodeine, dipipanone, fentanyl, hydro-
morphone, meptazinol, methadone, morphine, oxycodone,
papaveretum, pentazocine, pethidine, tapentadol and trama-
dol). Individuals with a prescription history of amitriptyline,
carbamazepine or nortriptyline were excluded from controls
since these are also frequently used to treat other disorders
(although these drugs are effective in neuropathic pain), and
the clinical information available from GoDARTS included
neither the indication for prescribing nor the presence of
these co-morbidities.
2.3 Genotyping and quality control
The GoDARTS diabetic individuals were genotyped by either
Affymetrix SNP6.0 chips (3673 patients) funded by the Well-
come Trust Case Control Consortium 2 (WTCCC2) project
(GoDARTS and UKPDS et al., 2011), or by Illumina Omni-
Express chips (3254 patients) funded by the Surrogate
markers for Micro- and Macro-vascular hard endpoints for
Innovative diabetes Tools (SUMMIT) project (Fagerholm
et al., 2012). Genotype data quality controls were under-
taken using the protocols that were established for the
WTCCC2 studies (GoDARTS and UKPDS et al., 2011) and
the SUMMIT studies (Fagerholm et al., 2012).
2.4 Statistical analysis
SHAPEIT and IMPUTE2 were used for imputation of non-
genotyped SNPs in the Affymetrix SNP6.0 chips and Illumina
OmniExpress chips using reference files from the 1000
genome phase I datasets (Howie et al., 2009; Delaneau et al.,
2011). IMPUTE2 uses an r2 score to evaluate the quality of a
specific imputed genotype. We used the recommended
r2 > 0.3 to filter out badly imputed SNPs. PLINK was the
main software for data manipulation, and routine quality
control steps were frequently applied during analyses
(removing SNPs with over 10% genotyping missing, or with
minor allele frequency less than 1%, or those that failed
Hardy–Weinberg tests p < 0.00001, and removing individuals
with more than 10% genotype data missing) (Purcell et al.,
2007). SNPs on the X and Y chromosomes and mitochondrial
SNPs were excluded from analyses. Population stratification
analysis was based upon multidimensional scaling integrated
in PLINK to detect any different ancestry in the cohort, with
a lambda value indicating the level of stratification. For good
quality datasets with minimum ancestry mixture, lambda
value should be close to 1. Removal of related samples was
based upon pi-hat >0.10 in PLINK. The p-values for SNP
associations were generated based upon Fisher’s exact test
integrated in PLINK. A p-value of less than 10−6 was consid-
ered to be suggestive of an association, warranting further
exploration. SNPnexus was applied for SNP functional anno-
tation and HaploView was used for generating Manhattan
plots (Barrett et al., 2005; Dayem Ullah et al., 2013).
LocusZoom was used for regional visualization (Pruim et al.,
2010). The corresponding Q-Q plot, a tool used to evaluate
differences between cases and controls caused by potential
confounders (different genotyping laboratories, different
DNA extraction methods, etc.), was generated by SNPEVG
(Wang et al., 2012). The whole workflow was shown in
Supporting Information Fig. S1. Narrow-sense heritability
was calculated by restricted maximum likelihood analysis
based upon common SNPs in both chips using GCTA, a tool
for genome-wide complex trait analysis (Lee et al., 2011).
Narrow-sense heritability is defined as the ratio of total phe-
notypic variance that is due to additive genetic effects (Lee
et al., 2011). Means of age, gender and BMI were compared
between cases and controls using independent t-test in SPSS
21 (IBM Corp, Armonk, NY, USA).
3. Results
In this general diabetic population, we identified 970
unrelated patients with a prescription history of one
or more of the five relevant drugs, representing
14.41% of the whole genotyped diabetic population.
Of these, 572 individuals (297 males and 275 females)
had positive monofilament test results in at least one
foot, making up 8.50% (572/6927) of the total geno-
typed diabetic population. Among these cases, 249
samples were genotyped on an Illumina platform and
323 samples were genotyped on an Affymetrix plat-
form. Of the remaining 5957 individuals, 310 indi-
viduals were removed either because they were
outlier in the population stratification analysis or
because they were related to another sample. Among
the rest, 2666 were identified as receiving 1 of the 16
opioid analgesics, and a further 490 individuals were
excluded since they had a prescription history of ami-
triptyline, carbamazepine or nortriptyline. Thus, we
identified and included 2491 controls, including 1503
males and 988 females. Cases therefore represented
18.7% of the eligible cohort (572/572 + 2491).
Among these controls, 1244 were genotyped on the
Illumina platform and 1247 were genotyped on the
W. Meng et al. GWAS on neuropathic pain
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Affymetrix platform. The average (mean ± standard
deviation) age and BMI in cases were 66.82 ± 10.69
and 33.28 ± 6.20, respectively. The average age and
BMI in controls were 66.86 ± 10.25 and 34.99 ± 6.98,
respectively. There was no statistical difference in age
between cases and controls, but the differences in
BMI and gender were statistically significant
(p < 0.01) (Supporting Information Table S1). Alto-
gether, 6,494,962 imputed SNPs survived from
routine quality control checking and imputation
quality r2 > 0.3. Since the multidimensional scaling
analysis for population stratification found a lambda
of 1.014 for the cleaned datasets, no further adjust-
ment based upon population stratification was applied
(Supporting Information Fig. S2). The corresponding
Q-Q plot is shown in Supporting Information Fig. S3.
Using Fisher’s exact test, there was a cluster appearing
in the Manhattan plot (only SNPs with p-values less
than 0.01 were used to generate the plot). Although
none of the SNPs reached genome-wide significance
(5 × 10−8), the cluster in chromosome 8p21.3
(Chr8p21.3), next to GFRA2 gene, still indicated pos-
sible associations (Fig. 1). The top SNP in this region
was rs17428041, with a lowest p-value of 1.77 × 10−7
and an odds ratio (OR) of 0.67 (95% confidence inter-
val: 0.57–0.78). Table 1 summarizes the significant
SNPs found in the region. Supporting Information
Fig. S4 shows the regional plot of the identified loci.
The heritability of neuropathic pain was estimated to
be 11.00% in this diabetic population. Since BMI and
gender were statistically different between cases and
controls, a logistic regression analysis adjusting for
these factors was performed. An extra peak was found
in the chromosome 12p13 (Supporting Information
Fig. S5). The p-value of the top SNP (rs11615866) is
1.08 × 10−6 and all the significant SNPs in the
chr8p21.3 and chr12p13 are summarized in the Sup-
porting Information Table S2.
Figure 1 Manhattan plot of the genome-wide
association study on neuropathic pain using
imputed single nucleotide polymorphisms.
X-axis represents 22 autosomes. Y-axis means
the −log 10 of p-values. The blue line is the
cut-off p-value of 10−6.
Table 1 Signiﬁcant SNPs in Chr8p21.3 next to GFRA2.
Chr SNP Position Gene
Minor
allele
Allele frequency
in cases (%)
Allele frequency
in controls (%) p-value OR Information about the SNP
8 rs4872521 21707713 Intergenic G 21.53 28.82 5.40 × 10−7 0.68 Imputed
8 rs4872522 21707844 Intergenic C 21.53 28.78 6.47 × 10−7 0.68 Imputed
8 rs10098807 21708824 Intergenic A 21.63 28.84 7.00 × 10−7 0.68 Imputed
8 rs11774105 21710146 Intergenic C 21.72 29.06 4.03 × 10−7 0.68 Imputed
8 rs17428041 21711431 Intergenic C 21.53 29.08 1.77 × 10−7 0.67 In the Illumina OmniExpress
8 rs17615364 21711580 Intergenic A 21.58 29.08 2.20 × 10−7 0.67 Imputed
8 rs11776842 21711651 Intergenic C 21.58 29.08 2.20 × 10−7 0.67 Imputed
8 rs12545534 21712401 Intergenic A 21.58 29.02 2.62 × 10−7 0.67 In the Illumina OmniExpress
8 rs11780601 21717841 Intergenic T 18.79 25.63 7.98 × 10−7 0.67 In the Illumina OmniExpress
p-values and ORs were calculated using Fisher’s exact test. Chr, chromosome; SNP, single nucleotide polymorphisms; OR, odds ratio.
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4. Discussion
This GWAS on neuropathic pain is based upon a well-
defined diabetic population in the United Kingdom,
using a pragmatic method of case definition and ascer-
tainment, and found a locus that may be associated
with painful diabetic neuropathy.
The assessment of neuropathic pain has been inter-
nationally standardized for primary care and specialist
settings (Haanpää et al., 2011; Jones and Backonja,
2013). However, these detailed assessment methods
are not suitable for population-based settings where
thousands of patients are to be phenotyped. Although
brief screening instruments, aimed at detecting pain
with neuropathic characteristics, have been used in
population-based research, they are imperfect and
have not been validated in general population settings
(Haanpää et al., 2011). Therefore, there is no practi-
cally applicable neuropathic pain gold standard phe-
notype for large human studies. No formal assessment
of (neuropathic) pain was made in the GoDARTS
cohort. An appropriate case definition of neuropathic
pain in a general population cohort is difficult to deter-
mine and there is currently no consensus on this
among researchers. A good phenotype definition will
cluster relatively homogeneous individuals with
similar clinical conditions. For genetic association
studies in particular, the wrong phenotype can lead to
false-positive and false-negative results (Belfer and
Dai, 2010). In our study, to achieve a relatively homo-
geneous and specific case population, we based the
case definition on a history of receiving drugs that are
mostly used only for neuropathic pain and on
recorded evidence of peripheral neuropathy, as shown
by responses to the monofilament test. This allowed us
to have a more homogeneous case population of dia-
betic neuropathic pain at the cost of decreased case
numbers. To achieve a homogeneous control popula-
tion, we removed diabetic individuals with a history of
using opioid analgesics. Any individuals using drugs
that are frequently used for treating both neuropathic
pain and other disorders were also excluded from con-
trols. While we recognize that other drugs (particu-
larly tricyclic antidepressants) are used in the
treatment of neuropathic pain, these are also fre-
quently used for other indications (mainly depres-
sion), and we therefore did not include individuals
identified only on receipt of these drugs as cases, to
optimize homogeneity. Similarly, the drugs we used
for case definition can be used for other indications. In
particular, duloxetine is indicated for depression, and
depression is relatively common in diabetes. However,
it is not a first-line treatment for depression, whereas
it is recommended as a first-line treatment for diabetic
neuropathy (NICE, 2013). We therefore decided to
include it in our case definition. Had we excluded
those receiving duloxetine, we would only have iden-
tified 516 cases, and our study would have been more
under-powered. Similarly, it has been demonstrated in
the United Kingdom that patients in primary care with
neuropathic pain are sometimes not prescribed with
the specific medications of known effectiveness
(Torrance et al., 2007, 2013; Hall et al., 2008). There-
fore, the controls in our study might have untreated
neuropathic pain, again diluting the results. Lack of
available data on pain status precludes assessment of
this effect. Methods of selecting homogeneous samples
in population-based GWAS have been attempted in
other common disorders (Meng et al., 2012a,b). In our
study, which had a mean age of 66.83 ± 10.61, 18.7%
of eligible participants were defined as cases. This is
similar to the proportion identified in a large
community-based UK study of diabetes of similar
mean age (63.60 ± 11.80), which found that 21% had
both neuropathy and positive responses to a validated
neuropathic pain symptom score (Abbott et al., 2011).
Furthermore, we found a similar gender distribution,
with a female : male ratio of 1.32, compared with 1.21
(Abbott et al., 2011), and this tends to support the
validity of our phenotype.
The significant SNP cluster was identified in
Chr8p21.3, with a lowest p-value of 1.77 × 10−7 at
rs17428041, spanning 10 kb from position 21707713
to position 21717841. The OR is 0.67 per copy of the
C allele of rs17428041, suggesting that this allele is
protective and that individuals with an additional C
allele in this SNP will have only 0.67 odds of being a
case compared to those with a T allele. The locus is
next to GFRA2 gene. GFRA2 encodes a glycosylphos-
phatidylinositol (GPI)-linked cell surface receptor for
both glial cell line-derived neurotrophic factor (GDNF)
and neurturin (NTN), but preferentially for NTN (Jing
et al., 1997). GDNF and NTN are two structurally
related, potent neurotrophic factors that are involved
in the control of neuron survival and differentiation
(Baudet et al., 2000). GDNF participates in the modu-
lation of nociceptive signals especially during neuro-
pathic pain states (Dong et al., 2005). Furthermore,
exogenous GDNF resulted in the relief of pain in dif-
ferent neuropathic pain rat models (Boucher et al.,
2000). In pancreatic cancer, which is closely linked
with neuropathic pain, NTN has been shown to be
produced by cancer cells, and to increase the cells’
biological properties, trigger neuroplastic alterations,
neural invasion and influence pain sensation via the
GFRA2 receptor (Wang et al., 2014). It was the GFRA2
W. Meng et al. GWAS on neuropathic pain
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receptor that mediated the pro-algesic effect of the
NTN/GFRA2 axis via the corresponding nociceptors
(Wang et al., 2014). NTN and GFRA2 were highly
unregulated, especially in intrapancreatic nerves and
the extracellular matrix (Wang et al., 2014). In a for-
malin test, the GFRA2 knockout mice showed a mark-
edly attenuated persistent phase response to stimuli,
suggesting a deficit in inflammatory pain responses
(Lindfors et al., 2006).
There were no sporadic SNPs passing p-value less
than 10−6. Although a p-value of 5 × 10−8 is often
accepted as the threshold for GWAS significance, this
might be too stringent (Do et al., 2014). No previous
evidence has been published linking the DOK2 gene
(next to the cluster in Chr8p21.3 from the opposite
direction) with any pain mechanisms. Therefore, we
have not further explored possible relationships
between the identified SNPs and DOK2 with neuro-
pathic pain. Narrow-sense heritability of diabetic neu-
ropathic pain was estimated to be 11.00% in this
diabetic population. This estimate excludes the contri-
bution of gene–gene interactions, gene–environment
interactions, etc., so the actual heritability of this phe-
notype is likely to be larger. This is the first report of
the heritability of neuropathic pain in humans,
although heritability has been demonstrated in rat
models and in other pain conditions in humans
(Devor et al., 2005; Hocking et al., 2012). Although
our heritability was relatively low in comparison with
other pain conditions, we have suggested that neuro-
pathic pain is a heritable trait and further genetic
research is warranted.
We had moderated power in this study due to the
limited number of cases. According to CaTS, using a
multiplicative model, we had 80% power to detect a
genotypic relative risk of 1.44 (or 0.69) for variants
with a minor allele frequency of 30% when the
disease prevalence in the population is 10% and the
significant level is 10−6 (Skol et al., 2006). However,
development and application of new criteria in select-
ing the maximum number of homogeneous cases will
enhance each individual SNP’s relative risk value
when evaluating power (Belfer and Dai, 2010). It is
important that such criteria are agreed internationally,
to allow future studies to replicate findings directly, in
different settings. A new and valid phenotyping
approach to neuropathic pain will not only improve
data and study quality but also help us to discover
novel mechanisms of pain at a molecular level. It has
the potential for identifying drug targets and eventu-
ally leading to better therapeutic management. The
monofilament test is a simple and inexpensive screen-
ing tool for identifying diabetic peripheral neuropathy
in clinical settings (Lee et al., 2003), although the
accuracy has been challenged (Dros et al., 2009).
Although there is no other published GWAS on
neuropathic pain, a GWAS study on chronic wide-
spread pain has identified that a locus at Chr5p15.2
between CCT5 and FAM173B might be associated with
the disorder (Peters et al., 2013). Another GWAS
study reported that the C allele of rs2952768 in the
Chr2q33.3 was associated with more analgesic
requirements in human (Nishizawa et al., 2014). Mul-
tiple GWAS studies have proposed genes (PRDM16,
TRPM8 or LRP1) and locus (Chr8q22.1) to be involved
in the migraine (Anttila et al, 2010; Chasman et al.,
2011). Therefore, there is growing evidence of the
involvement of SNPs in pain pathways, although
much more research is required, including particularly
replication studies, and consensus on feasible and rel-
evant phenotype ascertainment. None of the SNPs in
above-mentioned loci was positive in our study.
5. Conclusion
The analysis provided support that SNPs next to
GFRA2 in the Chr8p21.3 may be associated with neu-
ropathic pain in diabetes. We used a new approach in
this study to define neuropathic pain cases, based
upon routine prescribing data and evidence of neu-
ropathy, to achieve a reasonably homogeneous phe-
notype. Our next step is to attempt replication of
significant SNPs in independent cohorts and focus
upon the molecular mechanisms that may be respon-
sible for the association signals. The findings of these
studies will confirm hypothesized pathways of pain
mechanisms or suggest new ones, and provide possible
drug targets for pain treatment, with potential patient
benefit.
Author contributions
W.M. analysed the data and prepared the manuscript. H.A.D.
contributed to the manuscript preparation. N.R.Z., Y.L.,
L.A.D. and K.Z. contributed to the analysis of the GoDARTS
datasets. A.D.M. and H.M.C. reviewed the manuscript and
contributed to the discussion. C.N.A.P. made a significant
contribution to the discussion. B.H.S. supervised the overall
pain project and contributed significantly to the manuscript.
Acknowledgements
The authors of this manuscript would like to thank all the
patients recruited in the GoDARTS. The authors are grateful
to the Health Informatics Centre in the School of Medicine,
University of Dundee, for their help in data access.
GWAS on neuropathic pain W. Meng et al.
© 2014 The Authors. European Journal of Pain published by John Wiley & Sons Ltd on behalf of European Pain Federation - EFIC®6 Eur J Pain •• (2014) ••–••
References
Abbott, C.A., Malik, R.A., van Ross, E.R., Kulkarni, J., Boulton, A.J.
(2011). Prevalence and characteristics of painful diabetic neuropathy in
a large community-based diabetic population in the U.K. Diabetes Care
34, 2220–2224.
Anttila, V., Stefansson, H., Kallela, M., Todt, U., Terwindt, G.M., Calafato,
M.S., Nyholt, D.R., Dimas, A.S., Freilinger, T., Müller-Myhsok, B.,
Artto, V., Inouye, M., Alakurtti, K., Kaunisto, M.A., Hämäläinen, E., de
Vries, B., Stam, A.H., Weller, C.M., Heinze, A., Heinze-Kuhn, K.,
Goebel, I., Borck, G., Göbel, H., Steinberg, S., Wolf, C., Björnsson, A.,
Gudmundsson, G., Kirchmann, M., Hauge, A., Werge, T., Schoenen, J.,
Eriksson, J.G., Hagen, K., Stovner, L., Wichmann, H.E., Meitinger, T.,
Alexander, M., Moebus, S., Schreiber, S., Aulchenko, Y.S., Breteler,
M.M., Uitterlinden, A.G., Hofman, A., van Duijn, C.M.,
Tikka-Kleemola, P., Vepsäläinen, S., Lucae, S., Tozzi, F., Muglia, P.,
Barrett, J., Kaprio, J., Färkkilä, M., Peltonen, L., Stefansson, K., Zwart,
J.A., Ferrari, M.D., Olesen, J., Daly, M., Wessman, M., van den
Maagdenberg, A.M., Dichgans, M., Kubisch, C., Dermitzakis, E.T.,
Frants, R.R., Palotie, A., International Headache Genetics Consortium.
(2010). Genome-wide association study of migraine implicates a
common susceptibility variant on 8q22.1. Nat Genet 42, 869–873.
Attal, N., Cruccu, G., Baron, R., Haanpää, M., Hansson, P., Jensen, T.S.,
Nurmikko, T., European Federation of Neurological Societies. (2010).
EFNS guidelines on the pharmacological treatment of neuropathic pain:
2010 revision. Eur J Neurol 17, 1113–e88.
Barrett, A.M., Lucero, M.A., Le, T., Robinson, R.L., Dworkin, R.H.,
Chappell, A.S. (2007). Epidemiology, public health burden, and treat-
ment of diabetic peripheral neuropathic pain: A review. Pain Med 8,
S50–S62.
Barrett, J.C., Fry, B., Maller, J., Daly, M.J. (2005). Haploview: Analysis
and visualization of LD and haplotype maps. Bioinformatics 21, 263–265.
Baudet, C., Mikaels, A., Westphal, H., Johansen, J., Johansen, T.E.,
Ernfors, P. (2000). Positive and negative interactions of GDNF, NTN and
ART in developing sensory neuron subpopulations, and their collabo-
ration with neurotrophins. Development 127, 4335–4344.
Belfer, I., Dai, F. (2010). Phenotyping and genotyping neuropathic pain.
Curr Pain Headache Rep 14, 203–212.
Booth, J. (2000). Assessment of peripheral neuropathy in the diabetic
foot. J Tissue Viability 10, 21–25.
Boucher, T.J., Okuse, K., Bennett, D.L., Munson, J.B., Wood, J.N.,
McMahon, S.B. (2000). Potent analgesic effects of GDNF in neuropathic
pain states. Science 290, 124–127.
Chasman, D.I., Schürks, M., Anttila, V., de Vries, B., Schminke, U.,
Launer, L.J., Terwindt, G.M., van den Maagdenberg, A.M., Fendrich,
K., Völzke, H., Ernst, F., Griffiths, L.R., Buring, J.E., Kallela, M.,
Freilinger, T., Kubisch, C., Ridker, P.M., Palotie, A., Ferrari, M.D.,
Hoffmann, W., Zee, R.Y., Kurth, T. (2011). Genome-wide association
study reveals three susceptibility loci for common migraine in the
general population. Nat Genet 43, 695–698.
Chessell, I.P., Hatcher, J.P., Bountra, C., Michel, A.D., Hughes, J.P., Green,
P., Egerton, J., Murfin, M., Richardson, J., Peck, W.L., Grahames, C.B.,
Casula, M.A., Yiangou, Y., Birch, R., Anand, P., Buell, G.N. (2005).
Disruption of the P2X7 purinoceptor gene abolishes chronic inflamma-
tory and neuropathic pain. Pain 114, 386–396.
Dayem Ullah, A.Z., Lemoine, N.R., Chelala, C. (2013). A practical guide
for the functional annotation of genetic variations using SNPnexus.
Brief Bioinform 14, 437–447.
Delaneau, O., Marchini, J., Zagury, J.F. (2011). A linear complexity
phasing method for thousands of genomes. Nat Methods 9, 179–
181.
Devor, M., del Canho, S., Raber, P. (2005). Heritability of symptoms in the
neuroma model of neuropathic pain: Replication and complementation
analysis. Pain 116, 294–301.
Do, D.N., Ostersen, T., Strathe, A.B., Mark, T., Jensen, J., Kadarmideen,
H.N. (2014). Genome-wide association and systems genetic analyses of
residual feed intake, daily feed consumption, backfat and weight gain in
pigs. BMC Genet 15, 27.
Dong, Z.Q., Ma, F., Xie, H., Wang, Y.Q., Wu, G.C. (2005). Changes of
expression of glial cell line-derived neurotrophic factor and its receptor
in dorsal root ganglions and spinal dorsal horn during electroacupunc-
ture treatment in neuropathic pain rats. Neurosci Lett 376, 143–148.
Dros, J., Wewerinke, A., Bindels, P.J., van Weert, H.C. (2009). Accuracy of
monofilament testing to diagnose peripheral neuropathy: A systematic
review. Ann Fam Med 7, 555–558.
Dworkin, R.H., Malone, D.C., Panarites, C.J., Armstrong, E.P., Pham, S.V.
(2010). Impact of postherpetic neuralgia and painful diabetic peripheral
neuropathy on health care costs. J Pain 11, 360–368.
Fagerholm, E., Ahlqvist, E., Forsblom, C., Sandholm, N., Syreeni, A.,
Parkkonen, M., McKnight, A.J., Tarnow, L., Maxwell, A.P., Parving,
H.H., Groop, L., Groop, P.H., FinnDiane Study Group. (2012). SNP in
the genome-wide association study hotspot on chromosome 9p21
confers susceptibility to diabetic nephropathy in type 1 diabetes. Diabe-
tologia 55, 2386–2393.
Finnerup, N.B., Sindrup, S.H., Jensen, T.S. (2010). The evidence for
pharmacological treatment of neuropathic pain. Pain 150, 573–581.
GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group, Well-
come Trust Case Control Consortium 2, Zhou, K., Bellenguez, C.,
Spencer, C.C., Bennett, A.J., Coleman, R.L., Tavendale, R., Hawley,
S.A., Donnelly, L.A., Schofield, C., Groves, C.J., Burch, L., Carr, F.,
Strange, A., Freeman, C., Blackwell, J.M., Bramon, E., Brown, M.A.,
Casas, J.P., Corvin, A., Craddock, N., Deloukas, P., Dronov, S.,
Duncanson, A., Edkins, S., Gray, E., Hunt, S., Jankowski, J., Langford,
C., Markus, H.S., Mathew, C.G., Plomin, R., Rautanen, A., Sawcer, S.J.,
Samani, N.J., Trembath, R., Viswanathan, A.C., Wood, N.W., MAGIC
investigators, Harries, L.W., Hattersley, A.T., Doney, A.S., Colhoun, H.,
Morris, A.D., Sutherland, C., Hardie, D.G., Peltonen, L., McCarthy,
M.I., Holman, R.R., Palmer, C.N., Donnelly, P., Pearson, E.R. (2011).
Common variants near ATM are associated with glycemic response to
metformin in type 2 diabetes. Nat Genet 43, 117–120.
Haanpää, M., Attal, N., Backonja, M., Baron, R., Bennett, M., Bouhassira,
D., Cruccu, G., Hansson, P., Haythornthwaite, J.A., Iannetti, G.D.,
Jensen, T.S., Kauppila, T., Nurmikko, T.J., Rice, A.S., Rowbotham, M.,
Serra, J., Sommer, C., Smith, B.H., Treede, R.D. (2011). NeuPSIG guide-
lines on neuropathic pain assessment. Pain 152, 14–27.
Hall, G.C., Carroll, D., McQuay, H.J. (2008). Primary care incidence and
treatment of four neuropathic pain conditions: A descriptive study,
2002–2005. BMC Fam Pract 9, 26.
Hocking, L.J., Generation Scotland, Morris, A.D., Dominiczak, A.F.,
Porteous, D.J., Smith, B.H. (2012). Heritability of chronic pain in 2195
extended families. Eur J Pain 16, 1053–1063.
Howie, B.N., Donnelly, P., Marchini, J. (2009). A flexible and accurate
genotype imputation method for the next generation of genome-wide
association studies. PLoS Genet 5, e1000529.
Jensen, T.S., Backonja, M.M., Hernández Jiménez, S., Tesfaye, S., Valensi,
P., Ziegler, D. (2006). New perspectives on the management of diabetic
peripheral neuropathic pain. Diab Vasc Dis Res 3, 108–119.
Jensen, T.S., Baron, R., Haanpaa, M., Kalso, E., Loeser, J.D., Rice, A.S.,
Treede, R.D. (2011). A new definition of neuropathic pain. Pain 152,
2204–2205.
Jing, S., Yu, Y., Fang, M., Hu, Z., Holst, P.L., Boone, T., Delaney, J.,
Schultz, H., Zhou, R., Fox, G.M. (1997). GFRalpha-2 and GFRalpha-3
are two new receptors for ligands of the GDNF family. J Biol Chem 272,
33111–33117.
Jones, R.C. 3rd, Backonja, M.M. (2013). Review of neuropathic pain
screening and assessment tools. Curr Pain Headache Rep 17, 363.
Lee, S., Kim, H., Choi, S., Park, Y., Kim, Y., Cho, B. (2003). Clinical
usefulness of the two-site Semmes-Weinstein monofilament test for
detecting diabetic peripheral neuropathy. J Korean Med Sci 18, 103–107.
Lee, S.H., Wray, N.R., Goddard, M.E., Visscher, P.M. (2011). Estimating
missing heritability for disease from genome-wide association studies.
Am J Hum Genet 88, 294–305.
Lindfors, P.H., Võikar, V., Rossi, J., Airaksinen, M.S. (2006). Deficient
nonpeptidergic epidermis innervation and reduced inflammatory pain
in glial cell line-derived neurotrophic factor family receptor alpha2
knock-out mice. J Neurosci 26, 1953–1960.
McCarthy, M.I., Abecasis, G.R., Cardon, L.R., Goldstein, D.B., Little, J.,
Ioannidis, J.P., Hirschhorn, J.N. (2008). Genome-wide association
studies for complex traits: Consensus, uncertainty and challenges. Nat
Rev Genet 9, 356–369.
W. Meng et al. GWAS on neuropathic pain
© 2014 The Authors. European Journal of Pain published by John Wiley & Sons Ltd on behalf of European Pain Federation - EFIC® Eur J Pain •• (2014) ••–•• 7
Meng, W., Butterworth, J., Bradley, D.T., Hughes, A.E., Soler, V., Calvas,
P., Malecaze, F. (2012a). A genome-wide association study provides
evidence for association of chromosome 8p23 (MYP10) and 10q21.1
(MYP15) with high myopia in the French population. Invest Ophthalmol
Vis Sci 53, 7983–7988.
Meng, W., Butterworth, J., Malecaze, F., Calvas, P. (2012b). A linear
regression model to differentiate axial myopia from non-axial myopia.
Ophthalmic Genet 33, 53–55.
National Institute for Health and Care Excellence (NICE) UK. (2013)
Clinical Guideline 173. Neuropathic Pain – Pharmacological Management:
The Pharmacological Management of Neuropathic Pain in Adults in Non-
Specialist Settings (London: National Institute for Health and Care Excel-
lence). Retrieved from: http://guidance.nice.org.uk/CG173 (accessed
12 May 2014).
Nishizawa, D., Fukuda, K., Kasai, S., Hasegawa, J., Aoki, Y., Nishi, A.,
Saita, N., Koukita, Y., Nagashima, M., Katoh, R., Satoh, Y., Tagami, M.,
Higuchi, S., Ujike, H., Ozaki, N., Inada, T., Iwata, N., Sora, I., Iyo, M.,
Kondo, N., Won, M.J., Naruse, N., Uehara-Aoyama, K., Itokawa, M.,
Koga, M., Arinami, T., Kaneko, Y., Hayashida, M., Ikeda, K. (2014).
Genome-wide association study identifies a potent locus associated with
human opioid sensitivity. Mol Psychiatry 19, 55–62.
Nissenbaum, J., Devor, M., Seltzer, Z., Gebauer, M., Michaelis, M., Tal,
M., Dorfman, R., Abitbul-Yarkoni, M., Lu, Y., Elahipanah, T., delCanho,
S., Minert, A., Fried, K., Persson, A.K., Shpigler, H., Shabo, E., Yakir, B.,
Pisanté, A., Darvasi, A. (2010). Susceptibility to chronic pain following
nerve injury is genetically affected by CACNG2. Genome Res 20, 1180–
1190.
Norbury, T.A., MacGregor, A.J., Urwin, J., Spector, T.D., McMahon, S.B.
(2007). Heritability of responses to painful stimuli in women: A classical
twin study. Brain 130, 3041–3049.
Peters, M.J., Broer, L., Willemen, H.L., Eiriksdottir, G., Hocking, L.J.,
Holliday, K.L., Horan, M.A., Meulenbelt, I., Neogi, T., Popham, M.,
Schmidt, C.O., Soni, A., Valdes, A.M., Amin, N., Dennison, E.M.,
Eijkelkamp, N., Harris, T.B., Hart, D.J., Hofman, A., Huygen, F.J.,
Jameson, K.A., Jones, G.T., Launer, L.J., Kerkhof, H.J., de Kruijf, M.,
McBeth, J., Kloppenburg, M., Ollier, W.E., Oostra, B., Payton, A.,
Rivadeneira, F., Smith, B.H., Smith, A.V., Stolk, L., Teumer, A.,
Thomson, W., Uitterlinden, A.G., Wang, K., van Wingerden, S.H.,
Arden, N.K., Cooper, C., Felson, D., Gudnason, V., Macfarlane, G.J.,
Pendleton, N., Slagboom, P.E., Spector, T.D., Völzke, H., Kavelaars, A.,
van Duijn, C.M., Williams, F.M., van Meurs, J.B. (2013). Genome-wide
association study meta-analysis of chronic widespread pain: Evidence
for involvement of the 5p15.2 region. Ann Rheum Dis 72, 427–436.
Pruim, R.J., Welch, R.P., Sanna, S., Teslovich, T.M., Chines, P.S., Gliedt,
T.P., Boehnke, M., Abecasis, G.R., Willer, C.J. (2010). LocusZoom:
Regional visualization of genome-wide association scan results. Bioin-
formatics 26, 2336–2337.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender,
D., Maller, J., Sklar, P., de Bakker, P.I., Daly, M.J., Sham, P.C. (2007).
PLINK: A tool set for whole-genome association and population-based
linkage analyses. Am J Hum Genet 81, 559–575.
Skol, A.D., Scott, L.J., Abecasis, G.R., Boehnke, M. (2006). Joint analysis
is more efficient than replication-based analysis for two-stage genome-
wide association studies. Nat Genet 38, 209–213.
Smith, B.H., Macfarlane, G.J., Torrance, N. (2007). Epidemiology of
chronic pain, from the laboratory to the bus stop: Time to add under-
standing of biological mechanisms to the study of risk factors in
population-based research? Pain 127, 5–10.
Tarride, J.E., Collet, J.P., Choiniere, M., Rousseau, C., Gordon, A. (2006).
The economic burden of neuropathic pain in Canada. J Med Econ 9,
55–68.
Tesfaye, S., Chaturvedi, N., Eaton, S.E., Ward, J.D., Manes, C.,
Ionescu-Tirgoviste, C., Witte, D.R., Fuller, J.H., EURODIAB Prospective
Complications Study Group. (2005). Vascular risk factors and diabetic
neuropathy. N Engl J Med 352, 341–350.
Torrance, N., Ferguson, J.A., Afolabi, E., Bennett, M.I., Serpell, M.G.,
Dunn, K.M., Smith, B.H. (2013). Neuropathic pain in the community:
More under-treated than refractory? Pain 154, 690–699.
Torrance, N., Smith, B.H., Bennett, M.I., Lee, A.J. (2006). The epidemi-
ology of chronic pain of predominantly neuropathic origin. Results
from a general population survey. J Pain 7, 281–289.
Torrance, N., Smith, B.H., Watson, M.C., Bennett, M.I. (2007). Medica-
tion and treatment use in primary care patients with chronic pain of
predominantly neuropathic origin. Fam Pract 24, 481–485.
Trang, T., Beggs, S., Wan, X., Salter, M.W. (2009). P2X4-receptor-
mediated synthesis and release of brain-derived neurotrophic factor in
microglia is dependent on calcium and p38-mitogen-activated protein
kinase activation. J Neurosci 29, 3518–3528.
Wang, H., Sun, H., Della Penna, K., Benz, R.J., Xu, J., Gerhold, D.L.,
Holder, D.J., Koblan, K.S. (2002). Chronic neuropathic pain is accom-
panied by global changes in gene expression and shares pathobiology
with neurodegenerative diseases. Neuroscience 114, 529–546.
Wang, K., Demir, I.E., D’Haese, J.G., Tieftrunk, E., Kujundzic, K., Schorn,
S., Xing, B., Kehl, T., Friess, H., Ceyhan, G.O. (2014). The neurotrophic
factor neurturin contributes toward an aggressive cancer cell pheno-
type, neuropathic pain and neuronal plasticity in pancreatic cancer.
Carcinogenesis 35, 103–113.
Wang, S., Dvorkin, D., Da, Y. (2012). SNPEVG: A graphical tool for GWAS
graphing with mouse clicks. BMC Bioinformatics 13, 319.
Wang, X., Grace, P.M., Pham, M.N., Cheng, K., Strand, K.A., Smith, C., Li,
J., Watkins, L.R., Yin, H. (2013). Rifampin inhibits Toll-like receptor 4
signaling by targeting myeloid differentiation protein 2 and attenuates
neuropathic pain. FASEB J 27, 2713–2722.
Supporting Information
Additional Supporting Information may be found in the
online version of this article at the publisher’s web-site:
Figure S1. Workflow of the GWAS on neuropathic pain.
Figure S2. Multidimensional scaling analysis by PLINK to
detect population stratification.
Figure S3. Q-Q plot compared expected and observed
log 10(1/p) values.
Figure S4. Regional plot of Chr8p21.3 r2 represents the level
of linkage disequilibrium of SNPs.
Figure S5. Manhattan plot of the GWAS on neuropathic
pain using logistic regression with age, gender, body mass
index adjusted. X-axis represents 22 autosomes. Y-axis
means the −log 10 of p-values. The blue line is the cut-off
p-value of 10−5.
Table S1. Information on covariates between cases and con-
trols. Age and BMI (body mass index) are presented as
mean + standard deviation.
Table S2. Significant SNPs in the Chr8p21.3 and Chr12p13
loci.
GWAS on neuropathic pain W. Meng et al.
© 2014 The Authors. European Journal of Pain published by John Wiley & Sons Ltd on behalf of European Pain Federation - EFIC®8 Eur J Pain •• (2014) ••–••
